Want to see SE:GUARD full AI Analyst Report?
GUARD Stock Chart & Stats
kr1.38
-kr0.80(-4.00%)
At close: 4:00 PM EST
kr1.38
-kr0.80(-4.00%)
Day’s Range― - ―
52-Week Rangekr0.88 - kr27.00
Previous CloseN/A
Volume1.94K
Average Volume (3M)44.15K
Market Cap
kr30.25M
Enterprise Value-kr11.35
Total Cash (Recent Filing)kr40.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.07
Shares Outstanding20,167,631
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt provides structural financial flexibility for a clinical-stage biotech, lowering insolvency risk and interest burden. Over the next 2–6 months this preserves optionality for partnerships or milestone-based financing and reduces fixed-cost pressure versus leveraged peers.
Focused AKI Therapeutic PipelineA clear, narrow R&D focus on acute kidney injury creates a durable strategic advantage: targeted expertise, streamlined trial design, and clearer regulatory pathways. This specialization supports longer-term partnership and out-licensing appeal in an unmet medical-need area, independent of short-term market moves.
Improving Operating Loss TrendA meaningful reduction in annual net loss suggests better cost management or reprioritized R&D spend. If sustained, improving burn rates extend runway, reduce near-term financing pressure and make future financing rounds or partnerships less dilutive, enhancing long-term project execution prospects.
Bears Say
No Reported RevenueAbsence of operating revenue makes the company fully reliant on external capital events or milestone payments to fund R&D. That structural dependence increases binary outcome risk: long-term value hinges on clinical success or partner deals rather than ongoing commercial cash generation.
Persistent Heavy Cash BurnSustained large negative operating and free cash flow prevents self-funding of development and forces continuing external financing. Over multiple quarters this erodes optionality, pushes toward dilutive equity raises or reliance on nonrecurring financing, and raises execution risk for long-term programs.
Shrinking Equity Base / Dilution RiskA materially reduced equity base reflects accumulated losses and/or prior dilution, signaling limited built-up shareholder buffer. This structural capital erosion increases likelihood of future dilutive raises and reduces flexibility to pursue growth without adverse shareholder impact.
GUARD FAQ
What was Guard Therapeutics International AB’s price range in the past 12 months?
Guard Therapeutics International AB lowest stock price was kr0.88 and its highest was kr27.00 in the past 12 months.
What is Guard Therapeutics International AB’s market cap?
Guard Therapeutics International AB’s market cap is kr30.25M.
When is Guard Therapeutics International AB’s upcoming earnings report date?
Guard Therapeutics International AB’s upcoming earnings report date is Aug 20, 2026 which is in 25 days.
How were Guard Therapeutics International AB’s earnings last quarter?
Guard Therapeutics International AB released its earnings results on May 11, 2026. The company reported -kr0.315 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Guard Therapeutics International AB overvalued?
According to Wall Street analysts Guard Therapeutics International AB’s price is currently Overvalued.
Does Guard Therapeutics International AB pay dividends?
Guard Therapeutics International AB does not currently pay dividends.
What is Guard Therapeutics International AB’s EPS estimate?
Guard Therapeutics International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Guard Therapeutics International AB have?
Guard Therapeutics International AB has 20,167,631 shares outstanding.
What happened to Guard Therapeutics International AB’s price movement after its last earnings report?
Guard Therapeutics International AB reported an EPS of -kr0.315 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of Guard Therapeutics International AB?
Currently, no hedge funds are holding shares in SE:GUARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Guard Therapeutics International AB
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Intervacc AB
―
Immunicum AB
―
Corline Biomedical AB
―